Cargando…
Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m(2). Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient's a...
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624279/ https://www.ncbi.nlm.nih.gov/pubmed/29034246 http://dx.doi.org/10.1159/000477664 |
| _version_ | 1783268221465395200 |
|---|---|
| author | Mizuno, Hiroki Hoshino, Junichi Suwabe, Tatsuya Sumida, Keiichi Sekine, Akinari Oshima, Yoichi Oguro, Masahiko Kunizawa, Kyohei Kawada, Masahiro Hiramatsu, Rikako Hayami, Noriko Hasegawa, Eiko Yamanouchi, Masayuki Sawa, Naoki Takaichi, Kenmei Ubara, Yoshifumi |
| author_facet | Mizuno, Hiroki Hoshino, Junichi Suwabe, Tatsuya Sumida, Keiichi Sekine, Akinari Oshima, Yoichi Oguro, Masahiko Kunizawa, Kyohei Kawada, Masahiro Hiramatsu, Rikako Hayami, Noriko Hasegawa, Eiko Yamanouchi, Masayuki Sawa, Naoki Takaichi, Kenmei Ubara, Yoshifumi |
| author_sort | Mizuno, Hiroki |
| collection | PubMed |
| description | A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m(2). Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient's abdominal fullness began to improve and liver volume, indicating advanced polycystic liver disease (PLD), decreased from 9,750 mL to 8,345 mL after 17 months of tolvaptan treatment, though there was no significant change in kidney volume. This case indicates that tolvaptan may be a therapeutic option for hepatomegaly in patients with symptomatic PLD. |
| format | Online Article Text |
| id | pubmed-5624279 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | S. Karger AG |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-56242792017-10-13 Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease Mizuno, Hiroki Hoshino, Junichi Suwabe, Tatsuya Sumida, Keiichi Sekine, Akinari Oshima, Yoichi Oguro, Masahiko Kunizawa, Kyohei Kawada, Masahiro Hiramatsu, Rikako Hayami, Noriko Hasegawa, Eiko Yamanouchi, Masayuki Sawa, Naoki Takaichi, Kenmei Ubara, Yoshifumi Case Rep Nephrol Dial Case Report A 44-year-old Japanese woman with autosomal dominant polycystic kidney disease was admitted to our hospital for evaluation of abdominal distension. Her eGFR was 53.7 mL/min/1.73 m(2). Total kidney volume was 2,614 mL. Tolvaptan (60 mg/day) was started to treat renal involvement. The patient's abdominal fullness began to improve and liver volume, indicating advanced polycystic liver disease (PLD), decreased from 9,750 mL to 8,345 mL after 17 months of tolvaptan treatment, though there was no significant change in kidney volume. This case indicates that tolvaptan may be a therapeutic option for hepatomegaly in patients with symptomatic PLD. S. Karger AG 2017-07-19 /pmc/articles/PMC5624279/ /pubmed/29034246 http://dx.doi.org/10.1159/000477664 Text en Copyright © 2017 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/4.0/ This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
| spellingShingle | Case Report Mizuno, Hiroki Hoshino, Junichi Suwabe, Tatsuya Sumida, Keiichi Sekine, Akinari Oshima, Yoichi Oguro, Masahiko Kunizawa, Kyohei Kawada, Masahiro Hiramatsu, Rikako Hayami, Noriko Hasegawa, Eiko Yamanouchi, Masayuki Sawa, Naoki Takaichi, Kenmei Ubara, Yoshifumi Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease |
| title | Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease |
| title_full | Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease |
| title_fullStr | Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease |
| title_full_unstemmed | Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease |
| title_short | Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease |
| title_sort | tolvaptan for the treatment of enlarged polycystic liver disease |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624279/ https://www.ncbi.nlm.nih.gov/pubmed/29034246 http://dx.doi.org/10.1159/000477664 |
| work_keys_str_mv | AT mizunohiroki tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT hoshinojunichi tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT suwabetatsuya tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT sumidakeiichi tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT sekineakinari tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT oshimayoichi tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT oguromasahiko tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT kunizawakyohei tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT kawadamasahiro tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT hiramatsurikako tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT hayaminoriko tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT hasegawaeiko tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT yamanouchimasayuki tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT sawanaoki tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT takaichikenmei tolvaptanforthetreatmentofenlargedpolycysticliverdisease AT ubarayoshifumi tolvaptanforthetreatmentofenlargedpolycysticliverdisease |